Caribou is enrolling a 20-patient confirmatory cohort using the company's HLA matching strategy in the ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL). In H2 2025, Caribou ...

Controversies in the Treatment of Ischemia-Reperfusion Injury, ” will focus on past and current strategies for reducing the myocardial damage caused by IRI following percutaneous coronary intervention ...

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

In 2025, newly-designed clinical trials for people with cancer are providing new options and hope for patients and their ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The first clinical trial to test whether adults allergic to peanuts can be desensitized has shown great success with two ...

The trial will be a collaborative effort between the company, the Norwegian Cancer Society, and Cancer Research UK.

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

Two independent clinical trials have demonstrated the safety and potential effectiveness of stem cell-based therapies in ...